A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF NEDOSIRAN IN PEDIATRIC PATIENTS FROM BIRTH TO 5 YEARS OF AGE WITH PRIMARY HYPEROXALURIA AND RELATIVELY INTACT RENAL FUNCTION

Registry ID

DCR-PHXC-203

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

DICERNA PHARMACEUTICALS INC

Last update

2021-07-06

Conditions

• HYPEROXALURIA

Related clinical trials

• PHASE 1-2A SAFETY, TOLERABILITY, AND PHARMACODYNAMICS CONTROLLED STUDY OF NOV-001 IN HEALTHY VOLUNTEERS AND PATIENTS WITH ENTERIC HYPEROXALURIA
• EVALUATE THE SAFETY AND EFFICACY OF RELOXALIASE (OXALATE DECARBOXYLASE) IN PATIENTS WITH ENTERIC HYPEROXALURIA: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (URIROX-2)
• AN OPEN-LABEL ROLL-OVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DCR-PHXC SOLUTION FOR INJECTION (SUBCUTANEOUS USE) IN PATIENTS WITH PRIMARY HYPEROXALURIA

View on source registry